Tran, Andy T.
Okasha, Osama M.
Steinhaus, Daniel A.
Yousuf, Omair K.
Giocondo, Michael J.
Ramza, Brian M.
Wimmer, Alan P.
Gupta, Sanjaya K.
Funding for this research was provided by:
Bristol-Myers Squibb
AliveCor
Article History
Received: 1 January 2022
Accepted: 24 April 2022
First Online: 5 May 2022
Declarations
:
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.The study was approved by Saint Luke’s Mid America Heart Institute Institutional Review Board, IRB #17–043.
: Written informed consent was obtained from all individual participants included in the study.
: Permission granted.
: Dr. Tran reported receiving grants from the National Heart, Lung, and Blood Institute of the National Institutes of Health T32 training grant T32HL110837 during the conduct of the study. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Dr. Wimmer and Dr. Steinhaus receive speaker’s honoraria from Boston Scientific. Dr. Gupta receives research support from Medtronic, Abbott, Bristol Myers Squibb-Pfizer Alliance and has consulted for Medtronic, Boston Scientific and Respicardia. None of these disclosures were related to this research and should not represent a potential conflict of interest related to this manuscript.